MAP2K1 and thyroid gland carcinoma: Overall, combined AURKB and MEK1/2 inhibition decreases cell growth 64–87% (Figure 4), suggesting a potential benefit of combined MEK1/2 and AURKB inhibition in BRAF-mutant thyroid cancer cell lines.